Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)

Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease

(2021) Nathaniel Kleytman et al.   Molecular Genetics and Metabolism Reports

Real‐World Effectiveness of Eliglustat in Treatment‐Naïve and Switch Patients Enrolled in the International Collaborative Gaucher Group Gaucher Registry

(2020) Pramod K. Mistry et al.   AMERICAN JOURNAL OF HEMATOLOGY

Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review

(2020) Karin Luttropp et al.   Patient Preference and Adherence

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1

(2019) M. Judith Peterschmitt et al.   Orphanet Journal of Rare Diseases

Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase

(2018) Ari Zimran et al.   BLOOD CELLS MOLECULES AND DISEASES

Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project

(2018) Pilar Giraldo et al.   BLOOD CELLS MOLECULES AND DISEASES

Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies

(2017) Victoria F. Wagner et al.   Journal of Genetic Counseling

Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease

(2016) Ari Zimran et al.   BLOOD CELLS MOLECULES AND DISEASES

Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase

(2016) Laurie Smith et al.   MOLECULAR GENETICS AND METABOLISM

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials

(2015) Derralynn A. Hughes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease

(2014) Laura van Dussen et al.   Orphanet Journal of Rare Diseases

Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

(2009) Carla E.M. Hollak et al.   BLOOD CELLS MOLECULES AND DISEASES

A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1

(2009) P.S. Kishnani et al.   MOLECULAR GENETICS AND METABOLISM

Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy

(2007) M. Langeveld et al.   BLOOD CELLS MOLECULES AND DISEASES